GSK cancer treatment meets trial endpoint
GSK
1,353.50p
16:40 14/11/24
-0.62%
-8.50p
GSK on Friday unveiled positive headline results from a Phase 3 trial of its Jemperli endometrial cancer drug.
FTSE 100
8,071.19
16:49 14/11/24
n/a
n/a
FTSE 350
4,459.02
16:38 14/11/24
n/a
n/a
FTSE All-Share
4,417.25
16:54 14/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,794.96
16:38 14/11/24
0.96%
187.95
The company said Jemperli met its primary endpoint of investigator-assessed progression-free survival (PFS) and showed a “statistically significant and clinically meaningful benefit”.
Endometrial cancer is found in the inner lining of the uterus, known as the endometrium. It is the most common gynaecologic cancer in the US and the second most common gynaecologic cancer globally.
Approximately 15-20% of women with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis.
Reporting by Frank Prenesti for Sharecast.com